FDA Builds Quality Dashboard To Focus CMC Reviews And Inspections On Greatest Risks
Executive Summary
A dashboard tool US FDA is developing promises to liberate key information from the agency’s trove of CMC review documents, enabling greater consistency among reviews and a greater emphasis on the manufacturing issues that pose the greatest risks.
You may also be interested in...
FDA Relying More On Predictive Analytics To Help Monitor Quality Risks Of Sites During Pandemic
Analytics tool plays key role in helping agency oversee quality of 1,800 newly registered hand sanitizer facilities despite travel restrictions.
FDA’s Revised Quality Metrics Program: Voluntary Now, Mandatory Later
US FDA will establish mandatory quality metrics reporting through a formal rulemaking process that could take years. Meanwhile, a revised draft guidance lays out plans for voluntary quality metrics reporting that could begin by January 2018.
FDA Focuses ANDA Reviews on Basis of Risk
A risk-ranking pilot went so well that FDA’s Office of Generic Drugs has swiftly expanded use of the technique to help focus the attention of reviewers, swamped by GDUFA deadline-studded, QbD-packed ANDAs, on the quality issues that will have the greatest impact on patient safety.